Topical therapy II: retinoids, immunomodulators, and others

  • Paru R. Chaudhari
  • Dana K. Stern
  • Mark G. Lebwohl
Part of the Milestones in Drug Therapy book series (MDT)


Use of topical therapy for mild and moderate psoriasis continues to be a mainstay of treatment. The previous chapter introduced topical corticosteroids and vitamin D analogs as the most common therapies for psoriasis (see Tab. 1). Here the newly available topical retinoids and immunomodulators, along with the traditional therapies of tars, anthralin, and salicylic acid, will be discussed in detail.


Salicylic Acid Plaque Psoriasis Mometasone Furoate Psoriatic Lesion Tacrolimus Ointment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Chandraratna RA (1996) Tazarotene — first of a new generation of receptor-selective retinoids. Br J Dermatol 135Suppl 49: 18–25PubMedCrossRefGoogle Scholar
  2. 2.
    Duvic M, Nagpal S, Asano AT, Chandraratna RA (1997) Molecular mechanisms of tazarotene action in psoriasis. J Am Acad Dermatol 37: S18–24PubMedCrossRefGoogle Scholar
  3. 3.
    Nagpal S, Athanikar J, Chandraratna RA (1995) Separation of transactivation and AP1 antagonism functions of retinoic acid receptor alpha. J Biol Chem 270: 923–927PubMedCrossRefGoogle Scholar
  4. 4.
    Nagpal S, Patel S, Asano AT, Johnson AT, Duvic M, Chandraratna RA (1996) Tazarotene-induced gene 1 (TIG1), a novel retinoic acid receptor-responsive gene in skin. J Invest Dermatol 106: 269–274PubMedCrossRefGoogle Scholar
  5. 5.
    Nagpal S, Patel S, Jacobe H, DiSepio D, Ghosn C, Malhotra M, Teng M, Duvic M, Chandraratna RA (1997) Tazarotene-induced gene 2 (TIG2), a novel retinoid-responsive gene in skin. J Invest Dermatol 109: 91–95PubMedCrossRefGoogle Scholar
  6. 6.
    DiSepio D, Ghosn C, Eckert RL, Deucher A, Robinson N, Duvic M, Chandraratna RA, Nagpal S (1998) Identification and characterization of a retinoid-induced class II tumor suppressor/growth regulatory gene. Proc Natl Acad Sci USA 95: 14811–14815PubMedCrossRefGoogle Scholar
  7. 7.
    Foster RH, Brogden RN, Benfield P (1998) Tazarotene. Drugs 55: 705–711; discussion 712PubMedCrossRefGoogle Scholar
  8. 8.
    Weinstein GD, Koo JY, Krueger GG, Lebwohl MG, Lowe NJ, Menter MA, Lew-Kaya DA, Sefton J, Gibson JR, Walker PS (2003) Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol 48: 760–767PubMedCrossRefGoogle Scholar
  9. 9.
    Weinstein GD, Krueger GG, Lowe NJ, Duvic M, Friedman DJ, Jegasothy BV, Jorizzo JL, Shmunes E, Tschen EH, Lew-Kaya DA et al. (1997) Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. J Am Acad Dermatol 37: 85–92PubMedCrossRefGoogle Scholar
  10. 10.
    Tang-Liu DD, Matsumoto RM, Usansky JI (1999) Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis. Clin Pharmacokinet 37: 273–287PubMedCrossRefGoogle Scholar
  11. 11.
    Tauscher AE, Fleischer AB Jr, Phelps KC, Feldman SR (2002) Psoriasis and pregnancy. J Cutan Med Surg 6: 561–570PubMedGoogle Scholar
  12. 12.
    Lebwohl M, Ast E, Callen JP, Cullen SI, Hong SR, Kulp-Shorten CL, Lowe NJ, Phillips TJ, Rosen T, Wolf DI et al. (1998) Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis. J Am Acad Dermatol 38: 705–711PubMedCrossRefGoogle Scholar
  13. 13.
    Tzung TY, Wu JC, Hsu NJ, Chen YH, Ger LP (2005) Comparison of tazarotene 0.1% gel plus petrolatum once daily versus calcipotriol 0.005% ointment twice daily in the treatment of plaque psoriasis. Acta Derm Venereol 85: 236–239PubMedGoogle Scholar
  14. 14.
    Magliocco MA, Pandya K, Dombrovskiy V, Christiansen L, Wong Y, Gottlieb AB (2006) A randomized, double-blind, vehicle-controlled, bilateral comparison trial of bexarotene gel 1% versus vehicle gel in combination with narrowband UVB phototherapy for moderate to severe psoriasis vulgaris. J Am Acad Dermatol 54: 115–118PubMedCrossRefGoogle Scholar
  15. 15.
    Lebwohl MG, Breneman DL, Goffe BS, Grossman JR, Ling MR, Milbauer J, Pincus SH, Sibbald RG, Swinyer LJ, Weinstein GD et al. (1998) Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. J Am Acad Dermatol 39: 590–596PubMedCrossRefGoogle Scholar
  16. 16.
    Gollnick H, Menter A (1999) Combination therapy with tazarotene plus a topical corticosteroid for the treatment of plaque psoriasis. Br J Dermatol 140Suppl 54: 18–23PubMedCrossRefGoogle Scholar
  17. 17.
    Guenther LC, Poulin YP, Pariser DM (2000) A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis. Clin Ther 22: 1225–1238PubMedCrossRefGoogle Scholar
  18. 18.
    Koo JY, Martin D (2001) Investigator-masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. versus mometasone furoate cream b.i.d. in the treatment of plaque psoriasis. Int J Dermatol 40: 210–212PubMedCrossRefGoogle Scholar
  19. 19.
    Green L, Sadoff W (2002) A clinical evaluation of tazarotene 0.1% gel, with and without a highor mid-high-potency corticosteroid, in patients with stable plaque psoriasis. J Cutan Med Surg 6: 95–102PubMedGoogle Scholar
  20. 20.
    Dhawan SS, Blyumin ML, Pearce DJ, Feldman SR (2005) Tazarotene cream (0.1%) in combination with betamethasone valerate foam (0.12%) for plaque-type psoriasis. J Drugs Dermatol 4: 228–230PubMedGoogle Scholar
  21. 21.
    Bowman PH, Maloney JE, Koo JY (2002) Combination of calcipotriene (Dovonex) ointment and tazarotene (Tazorac) gel versus clobetasol ointment in the treatment of plaque psoriasis: a pilot study. J Am Acad Dermatol 46: 907–913PubMedCrossRefGoogle Scholar
  22. 22.
    Koo JY (1998) Tazarotene in combination with phototherapy. J Am Acad Dermatol 39: S144–148PubMedCrossRefGoogle Scholar
  23. 23.
    Hecker D, Worsley J, Yueh G, Kuroda K, Lebwohl M (1999) Interactions between tazarotene and ultraviolet light. J Am Acad Dermatol 41: 927–930PubMedCrossRefGoogle Scholar
  24. 24.
    Koo JY, Lowe NJ, Lew-Kaya DA, Vasilopoulos AI, Lue JC, Sefton J, Gibson JR (2000) Tazarotene plus UVB phototherapy in the treatment of psoriasis. J Am Acad Dermatol 43: 821–828PubMedCrossRefGoogle Scholar
  25. 25.
    Behrens S, Grundmann-Kollmann M, Schiener R, Peter RU, Kerscher M (2000) Combination phototherapy of psoriasis with narrow-band UVB irradiation and topical tazarotene gel. J Am Acad Dermatol 42: 493–495PubMedCrossRefGoogle Scholar
  26. 26.
    Lebwohl M, Ali S (2001) Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol 45: 487–498; quiz 499–502PubMedCrossRefGoogle Scholar
  27. 27.
    Behrens S, Grundmann-Kollmann M, Peter RU, Kerscher M (1999) Combination treatment of psoriasis with photochemotherapy and tazarotene gel, a receptor-selective topical retinoid. Br J Dermatol 141: 177PubMedCrossRefGoogle Scholar
  28. 28.
    Tzaneva S, Honigsmann H, Tanew A, Seeber A (2002) A comparison of psoralen plus ultraviolet A (PUVA) monotherapy, tacalcitol plus PUVA and tazarotene plus PUVA in patients with chronic plaque-type psoriasis. Br J Dermatol 147: 748–753PubMedCrossRefGoogle Scholar
  29. 29.
    Simpson D, Noble S (2005) Tacrolimus ointment: a review of its use in atopic dermatitis and its clinical potential in other inflammatory skin conditions. Drugs 65: 827–858PubMedCrossRefGoogle Scholar
  30. 30.
    Grassberger M, Baumruker T, Enz A, Hiestand P, Hultsch T, Kalthoff F, Schuler W, Schulz M, Werner FJ, Winiski A et al. (1999) A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 141: 264–273PubMedCrossRefGoogle Scholar
  31. 31.
    de Paulis A, Cirillo R, Ciccarelli A, de Crescenzo G, Oriente A, Marone G (1991) Characterization of the anti-inflammatory effect of FK-506 on human mast cells. J Immunol 147: 4278–4285PubMedGoogle Scholar
  32. 32.
    Hultsch T, Muller KD, Meingassner JG, Grassberger M, Schopf RE, Knop J (1998) Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner. Arch Dermatol Res 290: 501–507PubMedCrossRefGoogle Scholar
  33. 33.
    Inoue T, Katoh N, Kishimoto S (2006) Prolonged topical application of tacrolimus inhibits immediate hypersensitivity reactions by reducing degranulation of mast cells. Acta Derm Venereol 86: 13–16PubMedGoogle Scholar
  34. 34.
    Soter NA, Fleischer AB Jr, Webster GF, Monroe E, Lawrence I (2001) Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. J Am Acad Dermatol 44: S39–46PubMedCrossRefGoogle Scholar
  35. 35.
    Kempers S, Boguniewicz M, Carter E, Jarratt M, Pariser D, Stewart D, Stiller M, Tschen E, Chon K, Wisseh S et al. (2004) A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J Am Acad Dermatol 51: 515–525PubMedCrossRefGoogle Scholar
  36. 36.
    Paller AS, Lebwohl M, Fleischer AB Jr, Antaya R, Langley RG, Kirsner RS, Blum RR, Rico MJ, Jaracz E, Crowe A et al. (2005) Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. J Am Acad Dermatol 52: 810–822PubMedCrossRefGoogle Scholar
  37. 37.
    Draelos Z, Nayak A, Pariser D, Shupack JL, Chon K, Abrams B, Paul CF (2005) Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparison. J Am Acad Dermatol 53: 602–609PubMedCrossRefGoogle Scholar
  38. 38.
    Reitamo S, Wollenberg A, Schopf E, Perrot JL, Marks R, Ruzicka T, Christophers E, Kapp A, Lahfa M, Rubins A et al. (2000) Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. Arch Dermatol 136: 999–1006PubMedCrossRefGoogle Scholar
  39. 39.
    Allen A, Siegfried E, Silverman R, Williams ML, Elias PM, Szabo SK, Korman NJ (2001) Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch Dermatol 137: 747–750PubMedGoogle Scholar
  40. 40.
    Message FDA Available at: Accessed 20 July 2006
  41. 41.
    Berger TG, Duvic M, Van Voorhees AS, VanBeek MJ, Frieden IJ (2006) The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force. J Am Acad Dermatol 54: 818–823PubMedCrossRefGoogle Scholar
  42. 42.
    Yarosh DB, Pena AV, Nay SL, Canning MT, Brown DA (2005) Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation. J Invest Dermatol 125: 1020–1025PubMedCrossRefGoogle Scholar
  43. 43.
    Wijnen RM, Ericzon BG, Tiebosch AT, Buurman WA, Groth CG, Kootstra G (1992) Toxicology of FK506 in the cynomolgus monkey: a clinical, biochemical, and histopathological study. Transpl Int 5Suppl 1: S454–458PubMedGoogle Scholar
  44. 44.
    Novartis F FDA Briefing Statements. Pediatric Advisory Committee Meeting of the US Food and Drug Administration (2005)
  45. 45.
    Hultsch T, Kapp A, Spergel J (2005) Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology 211: 174–187PubMedCrossRefGoogle Scholar
  46. 46.
    Lebwohl M, Gower T (2006) A safety assessment of topical calcineurin inhibitors in the treatment of atopic dermatitis. MedGenMed 8: 8PubMedGoogle Scholar
  47. 47.
    Bieber T, Cork M, Ellis C, Girolomoni G, Groves R, Langley R, Luger T, Meurer M, Murrell D, Orlow S et al. (2005) Consensus statement on the safety profile of topical calcineurin inhibitors. Dermatology 211: 77–78PubMedCrossRefGoogle Scholar
  48. 48.
    Spergel JM, Leung DY (2006) Safety of topical calcineurin inhibitors in atopic dermatitis: evaluation of the evidence. Curr Allergy Asthma Rep 6: 270–274PubMedCrossRefGoogle Scholar
  49. 49.
    Kainz A, Harabacz I, Cowlrick IS, Gadgil SD, Hagiwara D (2000) Review of the course and outcome of 100 pregnancies in 84 women treated with tacrolimus. Transplantation 70: 1718–1721PubMedCrossRefGoogle Scholar
  50. 50.
    Paul C, Cork M, Rossi AB, Papp KA, Barbier N, de Prost Y (2006) Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years. Pediatrics 117: e118–128PubMedCrossRefGoogle Scholar
  51. 51.
    Steele JA, Choi C, Kwong PC (2005) Topical tacrolimus in the treatment of inverse psoriasis in children. J Am Acad Dermatol 53: 713–716PubMedCrossRefGoogle Scholar
  52. 52.
    Zonneveld IM, Rubins A, Jablonska S, Dobozy A, Ruzicka T, Kind P, Dubertret L, Bos JD (1998) Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study. Arch Dermatol 134: 1101–1102PubMedCrossRefGoogle Scholar
  53. 53.
    Remitz A, Reitamo S, Erkko P, Granlund H, Lauerma AI (1999) Tacrolimus ointment improves psoriasis in a microplaque assay. Br J Dermatol 141: 103–107PubMedCrossRefGoogle Scholar
  54. 54.
    Reitamo S, Rissanen J, Remitz A, Granlund H, Erkko P, Elg P, Autio P, Lauerma AI (1998) Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol 111: 396–398PubMedCrossRefGoogle Scholar
  55. 55.
    Queille-Roussel C, Paul C, Duteil L, Lefebvre MC, Rapatz G, Zagula M, Ortonne JP (2001) The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol 144: 507–513PubMedCrossRefGoogle Scholar
  56. 56.
    Freeman AK, Linowski GJ, Brady C, Lind L, Vanveldhuisen P, Singer G, Lebwohl M (2003) Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. J Am Acad Dermatol 48: 564–568PubMedCrossRefGoogle Scholar
  57. 57.
    Yamamoto T, Nishioka K (2000) Topical tacrolimus is effective for facial lesions of psoriasis. Acta Derm Venereol 80: 451PubMedCrossRefGoogle Scholar
  58. 58.
    Yamamoto T, Nishioka K (2003) Topical tacrolimus: an effective therapy for facial psoriasis. Eur J Dermatol 13: 471–473PubMedGoogle Scholar
  59. 59.
    Lebwohl M, Freeman AK, Chapman MS, Feldman SR, Hartle JE, Henning A (2004) Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol 51: 723–730PubMedCrossRefGoogle Scholar
  60. 60.
    Nagao K, Ishiko A, Yokoyama T, Tanikawa A, Amagai M (2003) A case of generalized pustular psoriasis treated with topical tacrolimus. Arch Dermatol 139: 1219PubMedCrossRefGoogle Scholar
  61. 61.
    Ortonne JP, van de Kerkhof PC, Prinz JC, Bieber T, Lahfa M, Rubins A, Wozel G, Lorette G (2006) 0.3% Tacrolimus gel and 0.5% Tacrolimus cream show efficacy in mild to moderate plaque psoriasis: Results of a randomized, open-label, observer-blinded study. Acta Derm Venereol 86: 29–33PubMedGoogle Scholar
  62. 62.
    Mrowietz U, Graeber M, Brautigam M, Thurston M, Wagenaar A, Weidinger G, Christophers E (1998) The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br J Dermatol 139: 992–996PubMedCrossRefGoogle Scholar
  63. 63.
    Gribetz C, Ling M, Lebwohl M, Pariser D, Draelos Z, Gottlieb AB, Zaias N, Chen DM, Parneix-Spake A, Hultsch T et al. (2004) Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol 51: 731–738PubMedCrossRefGoogle Scholar
  64. 64.
    Mrowietz U, Wustlich S, Hoexter G, Graeber M, Brautigam M, Luger T (2003) An experimental ointment formulation of pimecrolimus is effective in psoriasis without occlusion. Acta Derm Venereol 83: 351–353PubMedCrossRefGoogle Scholar
  65. 65.
    Ormerod AD, Shah SA, Copeland P, Omar G, Winfield A (2005) Treatment of psoriasis with topical sirolimus: preclinical development and a randomized, double-blind trial. Br J Dermatol 152: 758–764PubMedCrossRefGoogle Scholar
  66. 66.
    Carroll CL, Clarke J, Camacho F, Balkrishnan R, Feldman SR (2005) Topical tacrolimus ointment combined with 6% salicylic acid gel for plaque psoriasis treatment. Arch Dermatol 141: 43–46PubMedCrossRefGoogle Scholar
  67. 67.
    Everett MA, Daffer E, Coffey CM (1961) Coal tar and ultraviolet light. Arch Dermatol 84: 473–476PubMedGoogle Scholar
  68. 68.
    Goeckerman W (1925) Treatment of psoriasis. Northwest Med 24: 229–231Google Scholar
  69. 69.
    Stoughton RB, DeQuoy P, Walter JF (1978) Crude coal tar plus near ultraviolet light suppresses DNA synthesis in epidermis. Arch Dermatol 114: 43–45PubMedCrossRefGoogle Scholar
  70. 70.
    Goeckerman W (1931) Treatment of psoriasis. Continued observations on the use of crude coal tar and ultraviolet light. Arch Dermatol Syphilol 30: 446–450Google Scholar
  71. 71.
    Lee E, Koo J (2005) Modern modified ‘ultra’ Goeckerman therapy: a PASI assessment of a very effective therapy for psoriasis resistant to both prebiologic and biologic therapies. J Dermatolog Treat 16: 102–107PubMedCrossRefGoogle Scholar
  72. 72.
    Koo J, Lebwohl M (1999) Duration of remission of psoriasis therapies. J Am Acad Dermatol 41: 51–59PubMedCrossRefGoogle Scholar
  73. 73.
    Goodfield M, Kownacki S, Berth-Jones J (2004) Double-blind, randomised, multicentre, parallel group study comparing a 1% coal tar preparation (Exorex) with a 5% coal tar preparation (Alphosyl) in chronic plaque psoriasis. J Dermatolog Treat 15: 14–22PubMedCrossRefGoogle Scholar
  74. 74.
    Lin AN, Moses K (1985) Tar revisited. Int J Dermatol 24: 216–218PubMedGoogle Scholar
  75. 75.
    Sharma V, Kaur I, Kumar B (2003) Calcipotriol versus coal tar: a prospective randomized study in stable plaque psoriasis. Int J Dermatol 42: 834–838PubMedCrossRefGoogle Scholar
  76. 76.
    Thami GP, Sarkar R (2002) Coal tar: past, present and future. Clin Exp Dermatol 27: 99–103PubMedCrossRefGoogle Scholar
  77. 77.
    Silverman A, Menter A, Hairston JL (1995) Tars and anthralins. Dermatol Clin 13: 817–833PubMedGoogle Scholar
  78. 78.
    McGill A, Frank A, Emmett N, Turnbull DM, Birch-Machin MA, Reynolds NJ (2005) The antipsoriatic drug anthralin accumulates in keratinocyte mitochondria, dissipates mitochondrial membrane potential, and induces apoptosis through a pathway dependent on respiratory competent mitochondria. Faseb J 19: 1012–1014PubMedGoogle Scholar
  79. 79.
    Mahrle G (1997) Dithranol. Clin Dermatol 15: 723–737PubMedCrossRefGoogle Scholar
  80. 80.
    Ashton RE, Andre P, Lowe NJ, Whitefield M (1983) Anthralin: historical and current perspectives. J Am Acad Dermatol 9: 173–192PubMedCrossRefGoogle Scholar
  81. 81.
    Lebwohl M, Abel E, Zanolli M, Koo J, Drake L (1995) Topical therapy for psoriasis. Int J Dermatol 34: 673–684PubMedGoogle Scholar
  82. 82.
    Harris DR (1998) Old wine in new bottles: the revival of anthralin. Cutis 62: 201–203PubMedGoogle Scholar
  83. 83.
    Schaefer H, Farber EM, Goldberg L, Schalla W (1980) Limited application period for dithranol in psoriasis. Preliminary report on penetration and clinical efficacy. Br J Dermatol 102: 571–573PubMedCrossRefGoogle Scholar
  84. 84.
    Marsden JR, Coburn PR, Marks J, Shuster S (1983) Measurement of the response of psoriasis to short-term application of anthralin. Br J Dermatol 109: 209–218PubMedCrossRefGoogle Scholar
  85. 85.
    Volden G, Bjornberg A, Tegner E, Pedersen NB, Arles UB, Agren S, Brolund L (1992) Short-contact treatment at home with Micanol. Acta Derm Venereol Suppl (Stockh) 172: 20–22Google Scholar
  86. 86.
    Ramsay B, Lawrence CM, Bruce JM, Shuster S (1990) The effect of triethanolamine application on anthralin-induced inflammation and therapeutic effect in psoriasis. J Am Acad Dermatol 23: 73–76PubMedCrossRefGoogle Scholar
  87. 87.
    Endzweig-Gribetz CH, Brady C, Lynde C, Sibbald D, Lebwohl M (2002) Drug interactions in psoriasis: the pros and cons of combining topical psoriasis therapies. J Cutan Med Surg 6: 12–16PubMedCrossRefGoogle Scholar
  88. 88.
    Muller R, Naumann E, Detmar M, Orfanos CE (1987) Stability of cignolin (dithranol) in ointments containing tar with and without the addition of salicylic acid. Oxidation to danthron and dithranol dimer. Hautarzt 38: 107–111PubMedGoogle Scholar
  89. 89.
    Lebwohl M (1999) The role of salicylic acid in the treatment of psoriasis. Int J Dermatol 38: 16–24PubMedCrossRefGoogle Scholar
  90. 90.
    Huber C, Christophers E (1977) “Keratolytic” effect of salicylic acid. Arch Dermatol Res 257: 293–297PubMedCrossRefGoogle Scholar
  91. 91.
    Davies M, Marks R (1976) Studies on the effect of salicylic acid on normal skin. Br J Dermatol 95: 187–192PubMedCrossRefGoogle Scholar
  92. 92.
    Krochmal L, Wang JC, Patel B, Rodgers J (1989) Topical corticosteroid compounding: effects on physicochemical stability and skin penetration rate. J Am Acad Dermatol 21: 979–984PubMedGoogle Scholar
  93. 93.
    Hovding G (1981) Treatment of psoriasis of the scalp with betamethasone 17, 21-dipropionate plus salicylic acid lotion (‘Diprosalic’). Pharmatherapeutica 3: 61–66PubMedGoogle Scholar
  94. 94.
    Koo J, Cuffie CA, Tanner DJ, Bressinck R, Cornell RC, DeVillez RL, Edwards L, Breneman DL, Piacquadio DJ, Guzzo CA et al. (1998) Mometasone furoate 0.1%-salicylic acid 5% ointment versus mometasone furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis: a multicenter study. Clin Ther 20: 283–291PubMedCrossRefGoogle Scholar
  95. 95.
    Lebwohl M, Menter A, Koo J, Feldman SR (2004) Combination therapy to treat moderate to severe psoriasis. J Am Acad Dermatol 50: 416–430PubMedCrossRefGoogle Scholar
  96. 96.
    Proudfoot AT (1983) Toxicity of salicylates. Am J Med 75: 99–103PubMedCrossRefGoogle Scholar

Copyright information

© Birkhäuser Verlag/Switzerland 2008

Authors and Affiliations

  • Paru R. Chaudhari
    • 1
  • Dana K. Stern
    • 1
  • Mark G. Lebwohl
    • 1
  1. 1.Mount Sinai School of Medicine Department of DermatologyNew YorkUSA

Personalised recommendations